- Policy
- Benefit standards of Zometa Ready & Xgeva are expanded
- by Lee, Hye-Kyung Dec 23, 2020 06:09am
- The administration conditions for Zometa Ready (Zoledronic acid) of SciGen Korea and Xgeva (Denosumab) of Amgen Korea, which are used to treat patients with multiple myeloma and solid cancer bone metastasis, will be changed. Previously, both drugs were reimbursed only when they showed lytic findings on plain X-rays, normal on X-rays, or when
- Company
- Domestic companies won the first trial of 12 patents
- by Kim, Jin-Gu Dec 23, 2020 06:09am
- This year, domestic pharmaceutical companies have challenged 12 new patents. In 4 out of 12 patent disputes, generic companies have won all of them, and the remaining 8 cases have yet to be tried. According to the pharmaceutical industry on the 21st, a total of 12 patent disputes pending from January this year to this day. Daewoong and Cho
- Company
- “30-year presence of antihypertensive Novarsc to continue"
- by Eo, Yun-Ho Dec 22, 2020 06:13am
- Norvasc (amlodipine) is not the world’s first calcium channel blocker (CCB). However, it is undisputedly the most famous CCB. Launched in 1990s, Norvasc was not the first-in-class but it instigated a notable change in the market with the first once-daily administration. Some say the drug marked the early beginning of the current day co
- Policy
- “Just worrying about new pricing system gets you nowhere”
- by Eo, Yun-Ho Dec 22, 2020 06:12am
- A vast number of patients are suffering in vain and pain as more drugs are available without the healthcare insurance benefit. Now, the coverage on new drug is developing into an issue for the general South Korean public. Although the South Korean government tried to expand the scope of risk sharing agreement (RSA) and pharmacoeconomic e
- Company
- Boryung's FAH is expected to be released soon
- by Kim, Jin-Gu Dec 22, 2020 06:10am
- Boryung's hypertension combination drug is expected to be released in the second half of next year. If FAH is released next year as planned by Boryung, it will be the 7th 'Kanarb Family'. Interest is focused on whether to continue the Ducaro and Archave successes as the 5th and 6th Kanarb family this year. According to the pharmaceut
- Company
- First line therapy for NSNLC, starts of combination therapy
- by Eo, Yun-Ho Dec 22, 2020 06:09am
- Various combinations have been approved for NSNLC (non-small cell lung cancer), the most competitive field for new anticancer drugs. Competition is expected to intensify in the future as numerous studies are underway based on immuno-cancer drugs and targeted anti-cancer drugs. Lilly threw the hat into the ring in Korea. The company is
- Policy
- MFDS initiated a preliminary review of Pfizer's vaccine
- by Lee, Tak-Sun Dec 22, 2020 06:09am
- In Korea, the approval process for Pfizer's COVID-19 vaccine has also begun. The MFDS requested a preliminary review of non-clinical and clinical (Phase I, II, and III) data before Pfizer applied for a COVID-19 vaccine license on the 18th. On the same day, AstraZeneca also announced that it applied for an additional preliminary review of
- Company
- CKD to outrun SK and Hanmi with Xarelto patent challenge
- by Kim, Jin-Gu Dec 22, 2020 06:09am
- Chong Kun Dang is now the sole contender to challenge Bayer’s non-Vitamin K antagonist oral anticoagulants (NOAC) Xarelto (rivaroxaban) substance patent. As it overcame Xarelto’s formulation patent, Chong Kun Dang plans to enter the follow-on drug market faster than SK Chemicals and Hanmi Pharmaceutical, who won the preferential sales
- Policy
- What is the future COVID-19 vaccination plan?
- by Lee, Tak-Sun Dec 21, 2020 06:19am
- The government's plan and schedule for introducing COVID-19 vaccine have been established. It was introduced within the first quarter through a pre-purchase with AstraZeneca, and the contract with Pfizer, Modena, and Janssen, which contracts were delayed, will undergo import procedures after the second quarter. Therefore, early approval of
- Company
- Another effect of Botox, possible to treat hair loss
- by Dec 21, 2020 06:19am
- Following cosmetic surgery, botulinum toxin formulations are expanding their scope to treat hair loss. It is noteworthy as researches confirming the potential as a treatment for hair loss in Korea are ongoing. Dankook University dermatology professor Park Byeong-cheol confirmed the effect of botulinum toxin on hair loss improvement in the
